1. Academic Validation
  2. Inhibitor of apoptosis proteins (IAPs) may be effective therapeutic targets for treating endometriosis

Inhibitor of apoptosis proteins (IAPs) may be effective therapeutic targets for treating endometriosis

  • Hum Reprod. 2015 Jan;30(1):149-58. doi: 10.1093/humrep/deu288.
Takashi Uegaki 1 Fuminori Taniguchi 2 Kazuomi Nakamura 3 Mitsuhiko Osaki 4 Futoshi Okada 4 Osamu Yamamoto 5 Tasuku Harada 1
Affiliations

Affiliations

  • 1 Department of Obstetrics and Gynecology, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago 683-8504, Japan.
  • 2 Department of Obstetrics and Gynecology, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago 683-8504, Japan [email protected].
  • 3 Division of Laboratory Animal Science, Research Center for Bioscience and Technology, Tottori University Faculty of Medicine, Yonago, Japan.
  • 4 Pathological Biochemistry, Tottori University Faculty of Medicine, Yonago, Japan.
  • 5 Dermatology, Tottori University Faculty of Medicine, Yonago, Japan.
Abstract

Study question: What is the role of the inhibitor of Apoptosis proteins (IAPs) in human endometriotic tissues and a mouse model of endometriosis?

Summary answer: Four IAP proteins were expressed in endometriotic tissue indicating IAPs may be a key factor in the pathogenesis and progression of endometriosis.

What is known already: Overexpression of IAPs protects against a number of proapoptotic stimuli. IAPs (c-IAP1, c-IAP2, XIAP and Survivin) are expressed in human ectopic endometrial stromal cells (ESCs) from ovarian endometriomas.

Study design, size, duration: Forty-eight women with or without ovarian endometrioma are included in this study. BALB/c mice (n = 24) were used for the mouse endometriosis model. Mice with surgically induced endometriosis were treated with an IAP antagonist (BV6) for 4 weeks.

Participants/Materials, setting, methods: Human ectopic endometrial tissues from chocolate cysts and eutopic endometrial tissue were collected. ESCs were enzymatically isolated from these tissues. ESC proliferation was examined by 5-bromo-2'-deoxyuridine-enzyme-linked immunosorbent assay. IAPs expression in tissue derived from eutopic endometria and chocolate cysts was evaluated using real-time RT-PCR and immunohistochemistry. A homologous mouse endometriosis model was established by transplanting donor mouse uterine tissue into the abdominal cavities of recipient mice. After treating the mice with BV6 (i.p. 10 mg/ml), the extent of endometriosis-like lesions in mice was measured and proliferative activity assessed by Ki67 staining. All experiments were repeated a minimum of three times.

Main results and the role of chance: IAP (c-IAP1, c-IAP2, XIAP and Survivin) mRNA and protein in human ectopic endometrial tissues were expressed at higher levels than in eutopic endometrial tissues (P < 0.05). All four IAPs proteins were expressed in mouse endometriosis-like implants. BV6 inhibited BrdU incorporation of human ESCs (P < 0.05 versus control). BV6 also decreased the total number, weight, surface area and Ki67 positive cells in the endometriosis-like lesions in the mice (P < 0.05 versus control).

Limitations, reasons for caution: Endometriotic lesions were surgically induced in mice by transplanting mouse uterine tissue only, not human pathological endometriotic tissue. Furthermore, the effects of BV6 on human ESCs and mouse endometriosis-like lesions may differ between the species.

Wider implications of the findings: Our data support the hypothesis that IAPs are involved in the development of endometriosis, and therefore an inhibitor of IAPs has potential as a novel treatment for endometriosis.

Study funding/competing interests: This work was supported by KAKENHI (Japan Society for the Promotion of Science, Grant-in-Aid: to F.T.; 21592098 and to T.H.; 24659731) and Yamaguchi Endocrine Research Foundation. The authors have no conflicts of interest to disclose.

Keywords

BV6; endometrial stromal cells; inhibitor of apoptosis proteins family; mouse endometriosis model.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-16701
    99.50%, cIAP1/XIAP Antagonist
    IAP